The technology transfer of biological products is a complex process requiring control of multiple unit operations and parameters to ensure product quality and process performance. To achieve product commercialization, the technology transfer sending unit must successfully transfer knowledge about both the product and the process to the receiving unit. A key strategy for maximizing successful scale-up and transfer efforts is the effective use of engineering and shake-down runs to confirm operational performance and product quality prior to embarking on good manufacturing practice runs such as process performance qualification runs. We consider key factors to consider in making the decision to perform shake-down or engineering runs. We also present industry benchmarking results of how engineering runs are used in drug substance technology transfers alongside the main themes and best practices that have emerged. Our goal is to provide companies with a framework for ensuring the "right first time" technology transfers with effective deployment of resources within increasingly aggressive timeline constraints.
Introduction
As many biopharmaceuticals start to hit the patent cliff, companies face the immense challenge of improving their efficiency in developing and commercializing their pipeline. A key component of this objective is ensuring efficient technology transfer from research and development (R&D) to manufacturing operations. Figure 1 illustrates the key drivers that need to be balanced to ensure successful technology transfer: quality, technical, and business considerations. Ultimately, the technology transfer is considered successful by achieving "right first time" with successful lot release and a minimal number of nonconformances or out-of-specification (OOS) events. To demonstrate the effectiveness of the process scale-up and transfer, we need to analyze the critical process performance parameters, alongside the targets for product quality attributes and process yield and the ability to control within defined operating ranges. The quality and technical drivers need to be achieved against the backdrop of the business constraints. These include schedule and on-time delivery of the product for clinical trials and product launch, and financial and resource considerations.
In the first article of this series on technology transfer, we outlined the key elements of a robust technology transfer business process. In this article, we review some of the key strategies used to ensure successful technology transfer, focusing particularly on the use of engineering, shake-down, and wet test runs. There is debate in most companies on whether a test run is required to shake-down the process and equipment, confirming product quality prior to starting current good manufacturing practice (cGMP) manufacturing runs intended for human use in clinical studies or as commercial for-sale products. This would be analogous to the production of a prototype in, say, the automobile industry: Would you buy a car and accept the risk of driving your family in the prototype car that just came off the assembly line? The benefits in terms of identifying and rectifying potential issues in the 
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manufacturing process prior to cGMP production batches need to be weighed against the costs and potential timeline impacts. The BioPhorum Operations Technology Transfer Working Group conducted a benchmarking survey on this issue. Concepts and best practices on the approach to be used during technology transfer are discussed in this article.
Definition of Terms
It is important to ensure a common framework and terminology for a meaningful discussion of this topic. The technology transfer framework discussed here involves the transfer of biological drug substance processes from the sending to receiving unit (RU), the latter typically being a commercial manufacturing operation. This involves both process transfer (cell culture/fermentation, harvest and primary capture, and purification operations) and analytical transfer (method qualification, transfer, robustness, and validation or verification). There is considerable variation in the terminology used-engineering, shake-down, development runs, pilot test runs, wet runs-to name but a few. To set a baseline for the purposes of the benchmarking survey, a set of common definitions were established, as summarized in Table I .
Considerations for Shake-Down and Engineering Runs
Typically, shake-down and/or engineering runs are performed when a process is being transferred to a brand-new facility or significantly different facility, for example, partner organizations or contract manufacturing organizations (CMOs). This can be extended to cases where a significant amount of new equipment or a new technology base is being transferred, for example, a switch from a fed-batch to perfusion cell culture process. Other variables include process and product considerations and impact to the business:
• Is there a change in scale?
• Are there significant process or facility fit issues?
• Is the process being transferred aligned with the process platform?
• Are there particular product quality or stability issues?
• Is this a clinical or commercial technology transfer?
• Is there prior experience with the process, for example, with the process being run in the commercial launch facility to meet clinical demand?
• What is the acceptable probability of success and level of risk that the company is willing to accept? This may be different for a clinical versus a commercial (PPQ) technology transfer.
Beyond the need for a shake-down or engineering run, it is important to consider the number of runs required, the stagger between the runs, and also the stagger between the engineering and subsequent cGMP clinical/PPQ runs. The intervals should allow sufficient time for reviewing process performance (parametric data) such as growth, titer and metabolite profiles, step Experimental batches for execution of the process at scale for development of the final manufacturing process, automation, and operation. Shake-down runs are experimental, i.e., not used for clinical or commercial supply manufacturing. The shake-down run includes use of cell culture or product containing feed streams and requires a new product introduction (NPI) assessment (e.g. multi-product assessment)-this requirement is true from the shake-down run forward. This run serves to shake-down the process and equipment, prior to cGMP production.
Engineering First full-scale clinical (FSC) run
Full-scale lots of the final process to demonstrate process performance at the receiving unit (RU) prior to process performance qualification (PPQ). These may be cGMP for the manufacture of clinical or commercial material. The engineering run serves to shake-down the process and equipment, and confirm acceptable product quality. Clinical For human use Phase 1 to 3 lots Full-scale lots manufactured to supply clinical studies. These can function as engineering lots for PPQ later in a development program. Process performance qualification (PPQ)
Registration lots, consistency lots, validation lots, demonstration lots
Full-scale lots confirming that the manufacturing process as designed is capable of reproducible commercial manufacturing. These lots are included in the product registration dossier. The lots are performed under a preapproved PPQ protocol which details the PPQ plan and acceptance criteria. Commercial Routine commercial Full-scale lots manufactured to supply material for its intended (therapeutic) use. These may include the PPQ and continued process verification (CPV) lots and are targeted as product for commercial sale/distribution.
yields, chromatographic and filtration flux/pressure profiles, and it should enable adjustments of operational set-up and associated documentation. Critical product quality data needs to be turned around in an expedited manner at key steps in the process. Typically, during these runs, there needs to be a high level of support from the sending organization (development process experts, manufacturing sciences, or technical services) to help identify and trouble-shoot issues as they arise. It is critical that the change control system is adept at implementing changes. Tactically, this can take the form of planned deviations or emergency change controls to ensure forward processing in a timely manner. The stagger between runs should therefore include time to develop solutions to issues identified, comply with change control requirements, revise cGMP documentation, and allow for automation recipe modification and simulator testing, prior to being used in the manufacturing environment.
Finally, as highlighted in Figure 1 , the quality expectations in terms of the use of material from the engineering run should be considered: Will it be released for potential clinical use or is it only for R&D studies (NfHU)? The impact on the subsequent cGMP runs in terms of the number of non-conformances and OOSs should be considered, as it could affect the regulatory compliance perception and, therefore, the reputation of the company as a high-quality manufacturer. The re-use of critical materials like chromatography resins and membranes between engineering and commercial lots requires a sound strategy and robust tactical approach to ensure that product quality, patient safety, and regulatory compliance are not compromised.
Shake-down runs are therefore seen as an opportunity to confirm operational success prior to execution of the cGMP clinical/commercial campaign. Engineering runs combine this operational aspect with confirmation that acceptable product quality is attained prior to the execution of commercial runs. The benefits include
• Confirmation of process scale-up and process performance as expected.
• Confirmation of critical product quality attributes and product comparability being achieved.
• Confirmation of the effectiveness of any mitigation or corrective actions identified based on the process design, scale-up, and transfer efforts.
• An opportunity to train operators and make any revisions to cGMP documentation such as batch records (BRs), work instructions, and standard operating procedures (SOPs) prior to finalization.
• An opportunity to get an early start to cleaning verification or cleaning validation activities.
• An opportunity to test logistics of reprocessing steps (e.g., viral re-filtration, re-concentration).
• Material for use in development studies (e.g., stability, formulation, fill/finish, shipping qualification).
Shake-down or engineering runs are not a substitute for robust and effective simulator tests, and for noncell or product-based wet tests. Table II summarizes the pros and cons of performing the shake-down and engineering runs prior to cGMP clinical/PPQ runs. Table III summarizes the typical quality requirements 
Advantages Disadvantages
Opportunity to resolve process issues and confirm ability to proceed to clinical/commercial campaign.
Lengthens program timeline.
Cleaner data package for regulatory filings. Increases cost of performing the run (e.g., plant time and raw material costs). Flexibility to implement corrective action/preventative action (CAPA) in real time (see below).
If done as non-cGMP, material cannot be used in clinical or for potential commercial sale. Full-quality system (change control/deviations) is not "switched on" if performed as NfHU run.
Requires two standards in the commercial plant (cGMP versus non-cGMP standards). for the different types of run from wet runs through to routine commercial manufacturing runs.
Results from Benchmarking Survey about Approach to Shake-Down and Engineering Runs
Table IV summarizes the results of the benchmarking survey. The main themes that emerged are discussed below.
• Shake-down runs are considered experimental/developmental in nature, their main purpose being to finalize the process design and resolve scale-up issues. They are regarded as not for human use (NfHU). The need for shake-down runs depends on process, equipment constraints, and facility expertise. Completion of analytical transfer is not a prerequisite for shake-down runs.
• Engineering runs are considered the "full dress rehearsal" prior to PPQ runs. The focus is on process performance and product quality. It can be performed as cGMP for potential human use as long as quality standards are aligned to clinical cGMP (see Table III ). They are typically performed prior to PPQ runs but less so for clinical runs. Completion of analytical transfer is regarded as a prerequisite for engineering runs.
• The main benefit of these types of runs is to maximize the probability of success during the PPQ campaign.
• There is greater flexibility allowed within the quality system (non-conformances, change control, cGMP documentation) for shake-down runs but less so for engineering runs.
• The ability to downgrade the designation midway through the run is dependent on company preference and split evenly between respondents. It was not possible to upgrade the run designation, for example, shake-down run would not be repurposed as for clinical use or an engineering run as a PPQ run. Typically, if the run designation was stated up front, companies would take it through to the end to maximize the benefit gained in terms of process learnings. The responsibility for lot disposition decision was made by the quality unit based on the totality of data available. For example, if there were an unacceptable number of non-conformances, a batch may be rejected.
• There is a strong need for a comprehensive gap assessment to decide on the need for shake-down and engineering runs. It is best to do this early in the technology transfer process, typically during the site selection and initial planning phase. The decision should be finalized prior to formal technology transfer kick-off, as it affects the high-level budget and timeline established.
• The recommendation for engineering run typically comes from a joint technical technology transfer team with expertise in both the process and facility constraints. The decision needs strong acceptance by the RU because they are responsible for delivery and release of the manufacturing lots. The decision of whether to perform engineering/shakedown runs is made by a governance or steering committee that comprises senior leadership from both the sending unit (SU) and the RU.
• The question of who pays for shake-down/engineering run was not fully resolved in terms of a standard approach. It is dependent on whether it is an internal or external transfer, for example, to a CMO. Typically, shake-down runs were paid for by the R&D unit because they are developmental in nature, while engineering runs are paid for by the operations unit because they are to confirm process performance and product quality. However, there was no clear theme, and this was company-dependent to ensure compliance with financial policies and regulations.
• The cost impact can be minimized by using the engineering run for potential clinical studies if all quality requirements are met.
• A strategy that some companies use to minimize both raw material and plant time costs is to perform the shake-down run for only the upstream process. The material is then processed through at pilot or laboratory scale to confirm product quality. This strategy assumes there are good scale-down models, and the downstream unit operations and commercial equipment are well characterized and understood. If the engineering run is processed through the entire drug substance manufacturing process, the approach to resin and ultrafiltration membrane re-use needs to be addressed. A conservative approach is to discard these raw materials at the end of the shake-down or engineering run and start with new resin for the PPQ campaign. How- What value do you get from an engineering run?
• Increases confidence for successful PPQ campaign-readiness to proceed to PPQ • Confirms that operational parameters and product quality can be met at large scale • Allows release for clinical use 7a
How do you justify the value and cost of performing a shake-down run?
• Cost of shake-down batches is less than the cost of GMP batch failure (time and resources for investigation) • Risk assessment is performed to justify necessity based on unit operation and facility readiness • Shake-down run is performed at small scale, e.g., cell culture at full scale but downstream at laboratory or pilot scale 7b How do you justify the value and cost of performing an engineering run?
• Avoids failure during PPQ. Minimizes impact to regulatory submission and product launch • May be used for clinical supply 8a
In what phase should the team start discussions on the need for shake-down or engineering runs?
• By assessing the quality of the resin and process performance from the shake-down/engineering runs in terms of microbiological tests and carry-over considerations (protein, cleaning agents), the resin may be re-used for subsequent cGMP runs by demonstrating that it is still fit for use.
• The technology transfer stage gate process (discussed in the first article) is leveraged heavily to define the decision point for shake-down and engineering runs.
Conclusion
It is important to have a deliberate business process for gathering data and identifying knowledge gaps in the technology transfer process. This risk-based approach will enable the technology transfer team to make an informed decision on the need for shake-down and engineering runs to maximize the success of PPQ/ commercial campaigns. There are other options to mitigate risks identified, such as effective simulator testing, BR walk-downs, and wet testing using water or surrogate solutions. If shake-down or engineering runs are performed, it is important to have a clear set of evaluation criteria to assess the success of the technology transfer. The interval between runs should allow time to identify issues and implement corrective actions so that the subsequent cGMP clinical or PPQ runs are successful. As we establish process platforms and leverage learnings from shake-down runs, engineering runs, and clinical campaigns for subsequent technology transfers, there will likely be less need for performing shake-down and/or engineering runs. The decision points for these runs should be built into the technology transfer stage gate process with endorsement from senior leadership. Ultimately, a robust decision-making process will help companies realize faster, cost-effective and "right first time" technology transfer. 
